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Background: In COPD patients, hyperinflation impairs cardiac function. We examined whether
lung deflation improves oxygen pulse, a surrogate marker of stroke volume.
Methods: In 129 NETT patients with cardiopulmonary exercise testing (CPET) and arterial blood
gases (ABG substudy), hyperinflation was assessed with residual volume to total lung capacity
ratio (RV/TLC), and cardiac function with oxygen pulse (O2 pulseZ VO2/HR) at baseline and 6
months. Medical and surgical patients were divided into “deflators” and “non-deflators” based
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110 C.E. Come et al.experienced by 75% of surgical patients. We examined changes in O2 pulse at peak and similar
(iso-work) exercise. Findings were validated in 718 patients who underwent CPET without
ABGs.
Results: In the ABG substudy, surgical and medical deflators improved their RV/TLC and peak
O2 pulse (median ΔRV/TLC 18.0% vs. 9.3%, pZ 0.0003; median ΔO2 pulse 13.6% vs. 1.8%,
pZ 0.12). Surgical deflators also improved iso-work O2 pulse (0.53 mL/beat, pZ 0.04 at
20 W). In the validation cohort, surgical deflators experienced a greater improvement in peak
O2 pulse than medical deflators (mean 18.9% vs. 1.1%). In surgical deflators improvements in O2
pulse at rest and during unloaded pedaling (0.32 mL/beat, p< 0.0001 and 0.47 mL/beat,
p< 0.0001, respectively) corresponded with significant reductions in HR and improvements
in VO2. On multivariate analysis, deflators were 88% more likely than non-deflators to have
an improvement in O2 pulse (OR 1.88, 95% CI 1.30e2.72, pZ 0.0008).
Conclusion: In COPD, decreased hyperinflation through lung volume reduction is associated
with improved O2 pulse.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
There is increasing recognition of an association between
expiratory airflow limitation, hyperinflation, and cardiac
dysfunction in patients with chronic obstructive pulmonary
disease (COPD).1e5 This interaction may be mediated by
several factors including the association between COPD and
cardiovascular disease6,7 as well as lung-cardiac interde-
pendence with pulmonary hyperinflation in a closed
thoracic cage. In a large population-based study of normals
and subjects with mild COPD, Barr et al.8 demonstrated
that the extent of emphysema, as measured by computed
tomography (CT), and the severity of spirometrically
assessed airflow obstruction were significantly associated
with reduced left ventricular end diastolic volume, stroke
volume, and cardiac output. These findings were thought to
be due to a hyperinflated lung extrinsically compressing the
left ventricle (LV) or to an underappreciated degree of
vascular remodeling in subjects with emphysema. Recently,
in a study of 138 patients with mild-to-severe COPD, Watz
and colleagues5 showed that hyperinflation was signifi-
cantly associated with impaired LV filling and right
ventricular dysfunction, and that impaired LV filling was
independently associated with decreased exercise toler-
ance. The extent to which impaired cardiac function can be
improved by reducing hyperinflation may have implications
in patient management.
Several prior investigations in limited numbers of
patients have studied this question with mixed results3,9e13;
however, the general consensus is that reducing the degree
of hyperinflation may improve cardiac function. We postu-
lated that data from the patients enrolled in the National
Emphysema Treatment Trial (NETT),14 provided the best
available source of information to answer this question,
because patients had lung volumes and cardiopulmonary
exercise testing measured over time and were randomized
to lung volume reduction surgery (LVRS) or medical therapy.
We therefore used this cohort to determine whether
reduction of hyperinflation (assessed by the change in ratio
of residual volume to total lung capacity, ΔRV/TLC) with
LVRS improves left ventricular function as measured by
oxygen pulse (O2 pulse), a non-invasive correlate of stroke
volume.15Materials and methods
NETT compared the effects of LVRS vs. medical therapy on
survival and exercise capacity in COPD patients without
significant left ventricular dysfunction or pulmonary
vascular disease.12,14,16 All patients underwent cardiopul-
monary exercise (CPET) and pulmonary function testing
(PFT) at baseline (after completion of pulmonary rehabili-
tation) and post-randomization.17 A subset of patients
simultaneously participated in an exercise substudy with
blood gases (ABG substudy). Only patients who completed
all tests at baseline and at 6 months were included in this
analysis. The original NETT study was approved by the
institutional review board at each participating center, and
all patients provided written informed consent. Data anal-
ysis for the current study was approved by the Brigham and
Women’s Hospital IRB (2008P00157).
Exercise testing
CPET was performed while breathing 30% oxygen (CPET
protocol has previously been published in detail).17 In the
ABG substudy, oxygen uptake (VO2), carbon dioxide
production (VCO2), heart rate (HR), and workload were
measured every minute during exercise. Patients with
a respiratory exchange ratio (RERZ VCO2/VO2) at peak VO2
of <0.7 or >1.3 were excluded as values outside this range
suggest poor quality data.13,18,19 For the remaining (non-
ABG substudy) patients (validation cohort), VO2 was not
recorded and VCO2 was used to calculate VO2 using an RER
of 0.8.15 In this cohort, HR and VCO2 were measured at rest,
during unloaded pedaling, and at peak exercise. Patients
with different exercise protocols at baseline and 6 months
were excluded from this analysis.
Oxygen pulse
In COPD, the O2 pulse (VO2/HR) is used as a simple marker
of stroke volume (SV).1,9,10,13,20,21 Assuming a relationship
between cardiac output and VO2, changes in the O2 pulse
approximate changes in SV. This study’s primary outcome
was the percent change in peak O2 pulse from baseline (ΔO2
Figure 1 Consort diagram of the study cohorts. 1218 patients
were enrolled in NETT. Of those, 847 completed baseline and 6
month follow-up non-invasive cardiopulmonary exercise tests
(CPET) and had pulmonary function tests. Of the original 1218
patients, 238 were simultaneously enrolled in the ABG sub-
study. Of these, 129 had baseline and follow-up CPET data and
had normal respiratory exchange ratios (RER). These 129
overlapped completely with the 847 patients. Therefore, the
two groups were treated as separate cohorts (*): ABG substudy
(NZ 129), validation cohort (NZ 847 129Z 718). 67
patients from the ABG substudy cohort met criteria for inclu-
sion in the iso-work analysis.
Deflation and improvement in cardiac function 111pulse). In the ABG substudy, peak O2 pulse was calculated
using peak VO2 and HR at peak VO2. Baseline and follow-up
O2 pulse were compared at iso-work (5, 10, 15, and 20 W) in
a subset of patients who exercised for at least 3 min and
reached at least 25 W (further details regarding this anal-
ysis are available in the online data supplement, Figure 1S).
In the validation cohort, ΔO2 pulse was examined at rest,
during unloaded pedaling, and at peak exercise.
Pulmonary function tests and other clinical data
We chose RV/TLC to represent the degree of hyperinfla-
tion.10,11 Additional analysis using inspiratory capacity pre-
sented in the online data supplement (Figure 2S) provided
similar findings. ΔRV/TLC was expressed as percent change
from baseline. Anthropometric data, medications, and
resting room air blood gases were obtained at baseline and
at 6 months. The baseline CT scan distribution of emphy-
sema was classified as upper or non-upper lobe
predominant.14
Statistical analysis
We used the intention-to-treat principle. Medical and
surgical arms were subdivided into lung “deflators” and
“non-deflators.” Deflators were those patients who
experienced a decrease in the value of RV/TLC (ΔRV/TLC)
that was more negative than 4.43%. This threshold was
chosen based on the minimal improvement seen in 75% of
patients in the ABG substudy surgical cohort. Baseline
characteristics, ΔRV/TLC, and ΔO2 pulse between groups
were compared with parametric and non-parametric tests
as appropriate. Within group values at baseline and 6
months were compared using paired t-tests. To determine
whether deflation is associated with improvement in O2
pulse (ΔO2 pulse> 0), a logistic regression model was
created with improved O2 pulse (yes/no) at submaximal
exercise as the outcome and deflation (yes/no) as the
primary predictor. Covariates (all measured at baseline)
were selected on the basis of their biological plausibility
to confound the relationship between deflation and
improvement in O2 pulse. Finally, we tested for effect
modification of treatment assignment on the relationship
between deflation and improvement in O2 pulse by adding
an interaction term to the model. A p-value< 0.05 was
considered significant. Data was analyzed using SAS 9.1
(NC, USA).Results
Of the 1218 patients enrolled in NETT, 847 completed
baseline and 6 month follow-up CPETs and PFTs (Fig. 1). In
addition 238 of the 1218 patients participated in the ABG
substudy. One hundred and nine of these patients were
excluded because of missing data (99 patients) or because
their calculated RER fell outside of the pre-specified range
(10 patients). The remaining 129 patients overlapped
completely with the above 847 patients. Therefore, the
two groups were treated as separate cohorts: ABG substudy
(NZ 129), validation cohort (NZ 718).ABG substudy
Of the 129 patients from the ABG substudy, 67 had been
randomized to continued medical treatment and 62 to LVRS.
Baseline characteristics of these patients dichotomized by
deflator/non-deflator are presented in Table 1. Forty-eight
percent of the cohort deflated; of these deflators, 76%
were in the surgical arm and 24% were in the medical arm.
Deflators were more likely to have upper lobe predominant
emphysema (pZ 0.02). There was a significant inverse
correlation between ΔO2 pulse and ΔRV/TLC (Spearman
correlation coefficient 0.50, p-value< 0.0001). Surgical
deflators had a greater improvement in hyperinflation than
medical deflators (median 18.0% vs. 9.3%, pZ 0.0003;
Fig. 2A). Median absolute changes in RV and TLC in surgical
deflators were1.36 L (1.85 to 1.06) and 1.09 L (1.59
to 0.70) and in medical deflators 0.6 L (0.97 to 0.32)
and 0.27 L (0.47 to 0.17), respectively. Surgical and
medical non-deflators experienced worsening hyperinflation
(RV/TLC ratios increased by a median of 1.9% and 4.4%,
respectively). Compared with medical and surgical non-
deflators, surgical deflators had a significant improvement
in ΔO2 pulse at peak exercise. Surgical deflators also had
a higher ΔO2 pulse at peak exercise than medical deflators,
Table 1 Baseline characteristics of ABG substudy cohort dichotomized by deflator/non-deflator.
Characteristic Deflators, NZ 62 Non-deflators, NZ 67 p-Value
Surgical patients e no. (%) 47 (76%) 15 (22%) <0.0001
Age e yrs 68 (64e71) 67 (63e72) 0.75
Female sex e no. (%) 19 (31%) 14 (21%) 0.23
White race e no. (%) 57 (92%) 58 (87%) 0.40
BMI e kg/m2 24.9 (22.5e27.9) 25.6 (22.5e28.1) 0.79
Pack years 62 (46e86) 60 (40e77) 0.22
Upper lobe predominant distribution
of emphysema on CT e no. (%)a
43 (69%) 32 (48%) 0.02
FEV1 % predicted
b 28 (22e31) 28 (22e31) 0.82
TLC % predictedb 131 (116e135) 126 (115e137) 0.36
RV % predictedb 215 (184e250) 215 (179e249) 0.34
DLCO % predictedc 29 (22e36) 29 (24e35) 0.97
RV/TLC 0.63 (0.59e0.68) 0.60 (0.55e0.66) 0.07
Room air PaO2 e mmHg
d 64 (55e72) 63 (55e70) 0.44
Room air PaCO2 e mmHg
d 41 (38e44) 41 (37e45) 0.90
6 min walk distance e m 398 (330e457) 396 (342e444) 0.72
Maximal workload e W 39 (29e60) 39 (25e50) 0.52
O2 pulse e mL/beat 6.8 (5.92e8.72) 7.43 (5.9e9.07) 0.55
Medications
Beta blocker e no. (%) 1 (2%) 0 (0%) 0.48
Digoxin e no. (%) 6 (10%) 2 (3%) 0.15
Anti-hypertensive e no. (%) 11 (18%) 14 (21%) 0.66
Anti-arrhythmic e no. (%) 4 (6%) 4 (6%) 1.00
Long acting beta agonist e no. (%) 35 (56%) 35 (52%) 0.72
Short acting beta agonist e no. (%) 51 (82%) 62 (93%) 0.11
Anticholinergic e no. (%) 53 (85%) 62 (93%) 0.26
Oral bronchodilator e no. (%) 1 (2%) 1 (1%) 1.00
Inhaled corticosteroid e no. (%) 50 (81%) 44 (66%) 0.07
Definition of abbreviations: BMIZ body mass index, FEV1Z forced expiratory volume in one second, TLCZ total lung capacity,
RVZ residual volume, DLCOZ diffusing capacity of carbon monoxide.
Data presented as medians and interquartile ranges unless otherwise specified.
a Non-deflators missing data for one patient.
b Measurement obtained post-bronchodilator.
c Baseline DLCO was obtained prior to pulmonary rehabilitation; all other baseline pulmonary function measures were completed after
pulmonary rehabilitation.
d Deflators missing data for one patient.
112 C.E. Come et al.though this was not statistically significant (median 13.6%
vs. 1.8%, pZ 0.12; Fig. 2B).
To determine whether improved O2 pulse in deflators
was due to an improvement in the ventilatory limitation to
exercise rather than to an improvement in cardiovascular
function, absolute change in O2 pulse (6 month follow-up
minus baseline) was studied at submaximal (iso-work)
exercise: 5 W, 10 W, 15 W, and 20 W. Sixty-seven of the 129
patients, who met our predefined criteria outlined in the
Methods section and the online data supplement, were
considered in this iso-work analysis. This group was
comprised of 34 medical patients (11 deflators, 23 non-
deflators) and 33 surgical patients (24 deflators, 9 non-
deflators). Baseline characteristics of the surgical
patients, dichotomized by deflator/non-deflator, are pre-
sented in Table 2. Surgical deflators were significantly more
likely to have upper lobe predominant emphysema and
more hyperinflation at baseline than surgical non-deflators.
There was no difference between the groups in medication
use at any time. In surgical deflators, the difference
between baseline and follow-up O2 pulse widened at eachload, becoming significant at 20 W (Fig. 3A). This improve-
ment in O2 pulse corresponded with a significant decrease
in HR without a significant change in VO2 (Fig. 3C, B). These
findings were not replicated in the other three groups
(surgical non-deflators, medical deflators, and medical non-
deflators).Validation cohort
Of the 718 patients in this analysis, 335 were medical (263
non-deflators, 72 deflators) and 383 were surgical (80 non-
deflators, 303 deflators). Baseline characteristics of this
cohort dichotomized by deflator/non-deflator were similar
to those of the ABG substudy cohort (online data supple-
ment, Table 1S). Medication use did not differ between
deflators and non-deflators at any time. Surgical deflators
experienced a larger decrease in their mean RV/TLC than
medical deflators (18.2% vs. 10.0%, p< 0.0001). As in
the substudy, medical and surgical non-deflators had an
increase in their mean RV/TLC (4.6% and 3.6% respectively)
Figure 2 Percent change in ratio of residual volume to total
lung capacity (RV/TLC) from baseline to 6 month follow-up
(panel A) and percent change in O2 pulse from baseline to 6
month follow-up (panel B) according to treatment assignment
(medical vs. surgical) and deflator status for patients in the
ABG substudy. Med-NDZmedical non-deflator (NZ 52), Med-
DZmedical deflator (NZ 15), Surg-NDZ surgical non-deflator
(NZ 15), Surg-DZ surgical deflator (NZ 47).
Deflation and improvement in cardiac function 113with worsening of their O2 pulse (mean 3.2% and 4.5%
respectively). At six months, there was a greater improve-
ment in O2 pulse at peak exercise in surgical deflators than
medical deflators (mean 18.9% vs. 1.1%, p< 0.0001).
In surgical deflators, improvement in O2 pulse from
baseline to six month follow-up was significant at rest
(0.32 mL/beat, p< 0.0001), during unloaded pedaling
(0.47 mL/beat, p< 0.0001) and at peak exercise (1.16 mL/
beat, p< 0.0001). The improvements at iso-work were
associated with reductions in HR and improvements in VO2
(Fig. 4). Similar trends were observed in the medical
deflators at peak exercise and during unloaded pedaling. O2pulse worsened in surgical and medical non-deflators at
both unloaded pedaling and peak exercise. In surgical
deflators, mean hemoglobin decreased from baseline to
follow-up (0.42 g/dL, p< 0.0001), but mean oxygen satu-
ration increased minimally at rest (0.60%, p< 0.0001),
during unloaded pedaling (0.89%, p< 0.0001), and at peak
exercise (0.59%, pZ 0.0006).
Relationship between deflation and improvement
in O2 pulse
In the validation cohort, 386 of the 718 patients had an
improvement in O2 pulse at submaximal exercise. On
univariate analysis the odds of having an improved O2 pulse
for deflators was 2.23 times that of non-deflators (CI
1.70e3.09, p< 0.0001). This relationship was attenuated
though still highly significant after adjusting for treatment
assignment, age, sex, body mass index, distribution of
emphysema, FEV1 percent predicted, and DLCO percent
predicted (OR 1.88, 95% CI 1.30e2.72, pZ 0.0008). There
was no evidence of effect modification by treatment
assignment (interaction p> 0.05).
Discussion
In this study of 847 patients from NETT, a decrease in
hyperinflation as measured by the RV/TLC after LVRS, and
in some patients after medical therapy, was associated with
improved O2 pulse 6 months following randomization. The
improvement in O2 pulse was significant at rest, at peak
exercise, and at submaximal levels of exercise. The
improvement was associated with a decrease in HR and an
increase in oxygen uptake at iso-work. The effect was
independent of the means by which a patient was deflated,
and the magnitude of improvement was directly related to
the degree of deflation. These findings suggest that
decreased hyperinflation through effective lung volume
reduction is associated, at least in part, with improved
cardiac function.
Prior investigations have shown an association between
hyperinflation and impaired cardiac function.1,2,21 Two
studies demonstrated an improvement in O2 pulse following
LVRS in limited numbers of patients. In a study of 21
patients, Benditt and colleagues9 found significant
increases in maximal work, oxygen uptake, heart rate, O2
pulse, and minute ventilation at peak exercise three
months after LVRS. The improvement was thought to be
secondary to increases in ventilatory reserve. At iso-work
there was a non-significant increase in O2 pulse that the
authors suggested could be due to improved right or left
ventricular performance. In a single center case series of 25
patients with severe COPD, Cordova et al.10 found a signif-
icant decrease in RV/TLC ratio and a significant increase in
maximal O2 pulse three months after LVRS. In 20 of these
patients, the authors demonstrated a significant improve-
ment in O2 pulse at iso-time (though only a single time
point); as in our study, the iso-time improvement in O2
pulse was associated with a significant decrease in heart
rate from baseline. Non-significant improvements in O2
pulse at max work and at iso-time persisted at 6 months and
12 months. The lack of significance was likely due to the
Table 2 Baseline characteristics of surgical patients included in the ABG substudy iso-work analysis classified as deflators and
non-deflators.
Characteristic Deflators, NZ 24 Non-deflators, NZ 9 p-Value
Age e yrs 69 (64e72) 66 (66e69) 0.79
Female sex e no. (%) 9 (38%) 0 (0%) 0.04
White race e no. (%) 22 (92%) 7 (78%) 0.30
BMI e kg/m2 25.1 (23.7e28.2) 27.5 (24.6e28.4) 0.55
Pack years 61 (47e90) 40 (35e80) 0.23
Upper lobe predominant distribution
of emphysema on CT e no. (%)
21 (88%) 3 (33%) 0.005
FEV1 % predicted
a 28 (24e33) 29 (25e30) 0.89
TLC % predicteda 128 (113e135) 133 (119e136) 0.47
RV % predicteda 201 (181e237) 195 (180e228) 0.79
DLCO % predictedb 29 (23e39) 28 (21e30) 0.37
RV/TLC 0.62 (0.59e0.67) 0.52 (0.49e0.60) 0.01
Room air PaO2 e mmHg 64 (55e77) 55 (53e74) 0.58
Room air PaCO2 e mmHg 41 (38e43) 40 (37e45) 0.98
6 min walk distance e m 422 (349e457) 460 (422e486) 0.24
Maximal workload e W 43 (34e68) 58 (45e67) 0.24
O2 pulse e mL/beat 7.7 (6.03e9.89) 10.1 (7.96e12.36) 0.06
Definition of abbreviations: BMIZ body mass index, FEV1Z forced expiratory volume in one second, TLCZ total lung capacity,
RVZ residual volume, DLCOZ diffusing capacity of carbon monoxide.
Data presented as medians and interquartile ranges unless otherwise specified.
a Measurement obtained post-bronchodilator.
b Baseline DLCO was obtained prior to pulmonary rehabilitation; all other baseline pulmonary function measures were completed after
pulmonary rehabilitation.
114 C.E. Come et al.small number of patients (nZ 10). Our findings extend
these observations in a much larger cohort, thus facilitating
multivariate modeling to determine whether deflation is
independently associated with improvement in O2 pulse.
Additionally, comparison with a control group (patients
randomized to the medical arm), allowed demonstration
that improvements in hyperinflation were associated with
improvements in O2 pulse regardless of treatment mode. In
our study, medical deflators also experienced a non-
significant improvement in O2 pulse at 6 month follow-up.
The deflation in medical patients was smaller in magni-
tude which could account for the non-significant improve-
ment in O2 pulse in the medical deflators. These findings
are consistent with the effects seen in a smaller random-
ized controlled trial of bronchodilator therapy.21
Criner et al.17 suggested that improved exercise
capacity following LVRS could be due to improvements in
ventilatory mechanics with an improvement in ventilatory
reserve. Thus, an improvement in O2 pulse at peak exercise
could merely reflect a lifting of the ventilatory limit to
exercise and subsequently a longer duration of exercise.
This was true for lung “deflators” in this study who exer-
cised longer and reached a higher peak exercise heart rate.
However, the improvements in O2 pulse that we observed at
iso-time and submaximal exercise were not due to a longer
duration of exercise. We believe that at iso-work an
improvement in ventilatory mechanics results in improved
cardiac function manifested as a decrease in heart rate
with improved O2 pulse. Likewise, the minimal changes
seen in hemoglobin and oxygen saturation from baseline to
follow-up suggest a change in oxygen content is not
responsible for our findings at iso-time or at peak exercise.This study was not designed to determine the mecha-
nism by which heart function improved after LVRS though
the literature suggests several potential mechanisms. The
swings in intrathoracic pressure decrease at rest and more
so during exercise after LVRS.22,23 Decreases in the swing of
intrathoracic pressures may alter cardiac preload and/or
afterload thereby affecting cardiac function. Mineo et al.11
determined resting and exercise pulmonary hemodynamics
in 12 patients before and 6 months after LVRS. Changes in
rest vs. exercise right ventricular systolic volume and right
ventricular ejection fraction correlated well with reduction
in RV/TLC ratio (rZ0.68, pZ 0.01; rZ0.65, pZ 0.02,
respectively) suggesting that a reduction in hyperinflation
was a major determinant of the overall improvement in
right ventricular performance. Montes de Oca and
coworkers20 described a significant direct relationship
between inspiratory intrathoracic pressures and maximal
O2 pulse in 25 patients with very severe COPD, suggesting
that a reduction in left ventricular afterload may be the
most important mechanism in improving SV after LVRS.
Another potential mechanism, a decrease in pulmonary
vascular resistance, has not been observed.12,24 Finally,
LVRS may have anti-inflammatory effects affecting intrinsic
cardiac function,25 as described by Mineo and colleagues
who demonstrated an association between reduction in
lung hyperinflation after LVRS and reduction in levels of
circulating inflammatory mediators. Whatever the mecha-
nism, improvement in central hemodynamics after LVRS
may improve peripheral muscle oxygen delivery or utiliza-
tion as suggested by Berton and colleagues.26
We acknowledge limitations in this study. First, this was
a post hoc analysis with obvious survivor bias. Second, we
Figure 3 Comparison of baseline (:) and 6 month follow-up
(-) values for O2 pulse (panel A), oxygen uptake (VO2, panel
B), and heart rate (HR, panel C) at iso-work in surgical deflators
included in the ABG substudy (NZ 24). Data is presented as
means and standard deviations. *p< 0.05.
Figure 4 Comparison of baseline (:) and 6 month follow-up
(-) values for O2 pulse (panel A), oxygen uptake (VO2, panel
B), and heart rate (HR, panel C) at iso-work in surgical deflators
in the validation cohort (NZ 303). Data is presented as means
and standard deviations. *p< 0.05.
Deflation and improvement in cardiac function 115used a non-invasive surrogate for cardiac function. Most
investigators27e29 but not all,30 suggest that O2 pulse is
a good surrogate marker of SV in COPD. However, in this
study, each patient served as his/her own control, and
oxygen extraction was likely stable before and after LVRS.
We believe this is reasonable, because an improvement in
oxygen extraction after LVRS would bias our results against
our findings. Third, in this study, exercise testing was done
with all patients breathing 30% oxygen rather than room air.
While the increase in fractional inspired oxygen (FiO2)
might affect measurements of VO2, this would likely haveresulted in a systematic bias. Additionally, this issue was
addressed by using VCO2, which should not be appreciably
affected by an increased FiO2, to calculate VO2. Further-
more, using VCO2 and an RER value of 0.8 to calculate VO2
provided estimates of O2 pulse at maximal exercise that
correlated very well with estimates obtained when VO2 was
directly measured in the ABG substudy (Spearman correla-
tion coefficient 0.81, p< 0.0001). While the RER value may
increase as high as 0.95 during moderate exercise,15 our
116 C.E. Come et al.findings of improved O2 pulse at maximal exercise were
replicated during unloaded pedaling and at rest. Addition-
ally, when the analyses were done with assumed RER values
of 0.9 and 1.0, similar results were obtained (analyses not
shown). Notably during the baseline CPET in the ABG sub-
study cohort, median RER values at one minute and peak
exercise were 0.80 (0.76e0.87) and 0.86 (0.80e0.92),
respectively. Finally, the NETT cohort was fairly homoge-
neous, comprised of patients with severe COPD, so it is
unclear whether these results are generalizable to patients
with less hyperinflation.
In conclusion, our findings suggest that decreased
hyperinflation through effective lung volume reduction is
associated with improved left ventricular function as
measured by O2 pulse. Further studies are needed to
understand the clinical implications of these findings.
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